HansBiomed Corporation (KOSDAQ:042520)
South Korea · Delayed Price · Currency is KRW 40,000
-3,900 (-8.88%)
At close: Feb 6, 2026
HansBiomed Revenue
In the fiscal year ending September 30, 2025, HansBiomed had annual revenue of 89.78B KRW with 10.65% growth. HansBiomed had revenue of 23.71B in the quarter ending September 30, 2025, with 21.55% growth.
Revenue
89.78B
Revenue Growth
+10.65%
P/S Ratio
6.10
Revenue / Employee
324.11M
Employees
277
Market Cap
548.08B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 89.78B | 8.64B | 10.65% |
| Sep 30, 2024 | 81.14B | 3.11B | 3.98% |
| Sep 30, 2023 | 78.03B | 3.57B | 4.80% |
| Sep 30, 2022 | 74.46B | 15.36B | 25.99% |
| Sep 30, 2021 | 59.10B | -21.00B | -26.22% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| GC Cell | 170.13B |
| NIBEC | 32.96B |
| ROKIT Healthcare | 20.33B |
| S.Biomedics | 16.96B |
| JS Link | 16.14B |
| Y-Biologics | 3.61B |
| IntoCell | 1.68B |
| ToolGen | 1.07B |